WALTHAM, Mass., Nov. 14, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Investigational New Drug (IND) application submitted by Amgen for a second TAP compound is now active. This event triggers a $1 million milestone payment to ImmunoGen.
